Literature DB >> 18080921

Serum insulin like growth factor-1 (IGF-1) and insulin like growth factor binding protein-3 (IGFBP-3) levels in liver cirrhosis.

Onder Colakoğlu1, Bengür Taşkiran, Gül Colakoğlu, Servet Kizildağ, Fulya Ari Ozcan, Belkis Unsal.   

Abstract

BACKGROUND/AIMS: Impaired growth hormone-insulin like growth factor system in hepatic cirrhosis leads to cirrhosis-related complications. In this study, we aimed to investigate whether serum levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 are related to the level of hepatic dysfunction, clinical grade, and etiologic factors of the disease in patients with liver cirrhosis.
METHODS: Forty-two patients with liver cirrhosis who were diagnosed by means of clinical findings, endoscopy, imaging studies, or histopathology were enrolled in the study. An age- and sex-matched control group was comprised of 37 healthy controls with no signs of liver disease by clinical or laboratory findings. The demographic features (age, sex, height, and weight) and serum levels of liver function tests, urea, creatinine, sodium, potassium, insulin like growth factor-1, and insulin like growth factor binding protein- 3 and hemogram values were recorded for each individual. The patients were grouped according to Child Pugh classification and etiology.
RESULTS: Insulin like growth factor-1 and insulin like growth factor binding protein-3 levels were significantly lower in the cirrhotic group in comparison to the control group (p<0.005). A statistically significant decrease in levels of insulin like growth factor-1 and insulin like growth factor binding protein-3 was correlated with the degree of liver dysfunction, namely, lowest decrease in Child Pugh class A and highest decrease in class C. With respect to etiology, insulin like growth factor- 1 levels of alcohol-related liver cirrhosis were significantly lower than those of hepatitis B- related cirrhosis. There was no relation between insulin like growth factor binding protein-3 level and etiology. In the cirrhotic group, insulin like growth factor- 1 level was positively correlated with serum albumin and negatively correlated with serum creatinine and sodium levels and spleen size. Likewise, insulin like growth factor binding protein-3 level was positively correlated with serum albumin. There was a negative correlation between insulin like growth factor binding protein-3 level and serum bilirubin and spleen size.
CONCLUSIONS: Insulin like growth factor-1 and insulin like growth factor binding protein-3 levels are related to the level of clinical impairment and were independent of the etiology. They may serve as novel markers of hepatocellular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18080921

Source DB:  PubMed          Journal:  Turk J Gastroenterol        ISSN: 1300-4948            Impact factor:   1.852


  12 in total

1.  Relationship between serum circulating insulin-like growth factor-1 and liver fat in the United States.

Authors:  Shauna S Runchey; Edward J Boyko; George N Ioannou; Kristina M Utzschneider
Journal:  J Gastroenterol Hepatol       Date:  2014-03       Impact factor: 4.029

2.  Insulin-like growth factor-related components and the risk of liver cancer in a nested case-control study.

Authors:  Yasushi Adachi; Masanori Nojima; Mitsuru Mori; Yasutaka Matsunaga; Noriyuki Akutsu; Shigeru Sasaki; Takao Endo; Youichi Kurozawa; Kenji Wakai; Akiko Tamakoshi
Journal:  Tumour Biol       Date:  2016-09-23

3.  Circulating insulin-like growth factor-binding protein 3 as prognostic biomarker in liver cirrhosis.

Authors:  Carina Gabriela Correa; Bruno da Silveira Colombo; Marcelo Fernando Ronsoni; Pedro Eduardo Soares E Silva; Leonardo Fayad; Telma Erotides Silva; Letícia Muraro Wildner; Maria Luiza Bazzo; Esther Buzaglo Dantas-Correa; Janaína Luz Narciso-Schiavon; Leonardo de Lucca Schiavon
Journal:  World J Hepatol       Date:  2016-06-18

4.  Assessment of Growth and Development in Children With Hepatitis B Positivity.

Authors:  Tugba Sari; Erdal Eren; Suda Tekin Koruk
Journal:  Gastroenterology Res       Date:  2014-12-27

Review 5.  Insulin-Like Growth Factor (IGF) System in Liver Diseases.

Authors:  Agnieszka Adamek; Aldona Kasprzak
Journal:  Int J Mol Sci       Date:  2018-04-27       Impact factor: 5.923

Review 6.  Hepatocrinology.

Authors:  Sanjay Kalra; Saptarshi Bhattacharya; Pawan Rawal
Journal:  Med Sci (Basel)       Date:  2021-06-01

7.  Alterations of insulin-like growth factor I (IGF-I) and estradiol serum levels in chronic hepatitis C.

Authors:  Agnieszka Adamek; Aldona Kasprzak; Agnieszka Seraszek; Hanna Mikoś; Aleksandra Bura; Iwona Mozer-Lisewska
Journal:  Contemp Oncol (Pozn)       Date:  2012-07-06

Review 8.  The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets.

Authors:  Claudia Pivonello; Maria Cristina De Martino; Mariarosaria Negri; Gaia Cuomo; Federica Cariati; Francesco Izzo; Annamaria Colao; Rosario Pivonello
Journal:  Infect Agent Cancer       Date:  2014-08-20       Impact factor: 2.965

Review 9.  Fluid Biomarkers for Predicting the Prognosis of Liver Cirrhosis.

Authors:  Si-Hai Chen; Qin-Si Wan; Ting Wang; Kun-He Zhang
Journal:  Biomed Res Int       Date:  2020-03-20       Impact factor: 3.411

10.  Anthropometric, biochemical and clinical assessment of malnutrition among Egyptian children with chronic liver diseases: a single institutional cross-sectional study.

Authors:  Nehal El Koofy; Eman Mohamed Ibraheim Moawad; Mona Fahmy; Mona Anwar Mohamed; Hany Fathy Ahmed Mohamed; Ehab Mohamed Eid; Moushira Errfan Zaki; Rokaya Mohamed El-Sayed
Journal:  BMC Gastroenterol       Date:  2019-12-21       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.